About a year ago, I wrote one of my first articles here on Seeking Alpha, where I provided a valuation analysis on Teladoc (NYSE:TDOC). Trading at $12 a share at that time, I was valuing the stock at around $18. One year on, the stock price is at roughly $23, with 90%+ capital gain. On this occasion, I have decided to revalue Teladoc and come to the conclusion that the market is finally just about....More>>>
Shares ofGoPro (NASDAQ:GPRO) sank to fresh all-time lows on Monday, following an analyst downgrade (via Tech Trader Daily). Goldman Sachs analyst Simona Jankowski dropped her rating on GoPro from neutral to sell, while simultaneously slashing her price target down to a mere $6, or about 30% lower than where shares closed on Friday.
Jankowski lays out a handful of concerns, including saturation....More>>>
“Mors tua, vita mea” (literally “your death is my life) probably was the motto that gladiators, in the ancient Rome, recited before entering in the Coliseum and fighting for their life. Over and above its literal translation, this Latin expression means that what is a damage for one person is often an advantage for another. There can only be one winner in a competition; that is....More>>>
On Tuesday, our Under the Radar Moversnewsletter suggested shorting small cap cloud-based services stockLogMeIn Inc (NASDAQ: LOGM):
This one’s been on our bearish watchlist for a while, as it’s been overbought and ripe for a pullback for quite some time now. The stock finally broke down today, with LOGM shares breaking below the 100-day moving average line at $98.34. Logmein was....More>>>
When John Milligan speaks, people listen — especially if they’re Gilead Sciences (NASDAQ:GILD) shareholders.
The big biotech’s CEO and its CFO Robin Washington sat down to field questions at the RBC Capital Markets 2017 Healthcare Conference in New York City on Wednesday. Milligan spoke directly to some of the most pressing concerns for Gilead shareholders. Here are three....More>>>